Regulation of Proinflammatory Cytokine Responses by a Caspase-8-N4BP1 Axis
Caspase-8-N4BP1 轴对促炎细胞因子反应的调节
基本信息
- 批准号:10704065
- 负责人:
- 金额:$ 44.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-13 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:Adaptor Signaling ProteinAffectAgonistAnti-Inflammatory AgentsApoptosisApoptoticAppointmentAreaAutoimmunityAwardBinding ProteinsBiochemistryBiological ProcessBiologyCASP8 geneCD95 AntigensCareer MobilityCaspaseCell Culture TechniquesCell DeathCellsCellular ImmunologyCessation of lifeClinicalClinical CompetenceClinical PathologyClustered Regularly Interspaced Short Palindromic RepeatsCommunicable DiseasesCompetenceDataDedicationsDiseaseDisease ProgressionEndowmentEvaluationFacultyFundingGene ExpressionGeneticGenetic TranscriptionGenetically Engineered MouseGoalsHealthHigh-Throughput Nucleotide SequencingHumanImageImmuneImmune System DiseasesImmunityImmunologic Deficiency SyndromesImmunologic ReceptorsImpairmentIn VitroInflammationInflammatoryInflammatory Response PathwayInstitutionKnock-inKnowledgeLaboratoriesLeadershipLicensingLigandsLinkMacrophageMalignant NeoplasmsMediatingMedicalMedicineMentorsMentorshipMolecularMutationNF-kappa BNatural ImmunityNerve DegenerationPathologicPathologyPathway interactionsPatientsPeer ReviewPhasePhosphotransferasesPhysiciansPositioning AttributePostdoctoral FellowProductionProteinsPublicationsRegulationResearchResearch PersonnelResearch ProposalsResidenciesResistanceRoleRotationScientistSeriesSignal PathwaySignal TransductionSourceStudentsSystemT-LymphocyteTBK1 geneTLR1 geneTLR3 geneTLR4 geneTLR7 geneTNF geneTNFSF6 geneTechniquesTechnologyTherapeutic InterventionToll-like receptorsTrainingTranscriptTransferable SkillsUnited States National Institutes of HealthUniversitiesVisitWorkadaptive immunityautoimmune lymphoproliferative syndromeautoinflammatory diseasescareerconstrictioncytokineexpectationexperiencefaculty supportgenome editinggenome-wideimmune activationin vivoinsightinstructormeetingsnew therapeutic targetnovelnovel therapeutic interventionphosphoproteomicsresponsesenior facultysingle cell analysisundergraduate student
项目摘要
Project Summary/Abstract
Rare monogenic immune disorders have illuminated key aspects of inflammation, but many of the underlying
mechanisms remain poorly understood. For example, autoimmune lymphoproliferative syndrome (ALPS), a
disorder in which T cells fail to undergo apoptosis, is most often caused by genetic defects in the death receptor
FAS or its ligand FASL. However, mutations in caspase-8 or its adaptor FADD – which mediate cell death
downstream of FAS – cause a combination of ALPS plus severe immunodeficiency. Since immunodeficiency is
not generally observed in patients with FAS or FASL mutations, I hypothesized that FADD-caspase-8 must have
an apoptosis-independent function downstream of an immune receptor other than FAS. Indeed, I recently
discovered that activation of multiple immune receptors elicits the caspase-8-mediated cleavage of Nedd4-
binding protein 1 (N4BP1), a novel cytokine suppressor. This represents a critical point of regulation during
inflammation. Notably, deletion of N4BP1 does not ordinarily affect the TRIF-dependent subset of toll-like
receptors (TLRs) that activate caspase-8 (e.g., TLR3 and TLR4). However, the impaired cytokine production of
caspase-8-deficient macrophages stimulated with a TLR4 agonist is restored to normal by co-deletion of N4BP1.
In contrast, N4BP1 deletion leads to exorbitant cytokine responses by the TRIF-independent TLRs (e.g., TLR1/2,
TLR7 and TLR9) that do not directly activate caspase-8. Thus, N4BP1 cleavage by caspase-8 inactivates the
anti-inflammatory activity of intact, un-cleaved N4BP1. These findings offer a novel mechanistic explanation for
immunodeficiency caused by FADD-caspase-8 mutations, whereby the inability to cleave N4BP1 results in its
aberrant persistence and constriction of cytokine responses. Like TLR3 and TLR4 agonists, tumor necrosis factor
(TNF) also leads to caspase-8 cleavage of N4BP1, endowing TNF with the ability to inactivate N4BP1 and
thereby license cytokine production by the TRIF-independent TLRs. This latter finding highlights a key point of
molecular crosstalk between the TNF and TLR systems that converges on caspase-8 cleavage of N4BP1. In the
current proposal, I have linked the mechanism by which N4BP1 suppresses cytokine production to a series of
proteins with both previously recognized and heretofore unknown roles in inflammation. In Aim 1, I will attempt
to decipher the mechanism by which N4BP1 controls the activity of this novel kinase-dependent pathway that
suppresses inflammation. In Aim 2, I will dissect how N4BP1 suppresses late phase inflammatory gene
expression using genome-scale technologies. In Aim 3, I will explore the mechanisms and in vivo consequences
of signal integration by the TNF-caspase-8-N4BP1 axis. Together, these aims will provide novel mechanistic
insights explaining a key regulatory circuit underlying inflammation. They also will serve to launch my
independent research career.
项目概要/摘要
罕见的单基因免疫疾病阐明了炎症的关键方面,但许多潜在的原因
例如,自身免疫性淋巴增殖综合征(ALPS)的机制仍知之甚少。
T 细胞无法凋亡的疾病通常是由死亡受体的遗传缺陷引起的
FAS 或其配体 FASL 然而,caspase-8 或其接头 FADD 的突变会介导细胞死亡。
FAS 下游 – 导致 ALPS 和严重免疫缺陷的结合,因为免疫缺陷是
在具有 FAS 或 FASL 突变的患者中通常没有观察到,我认为 FADD-caspase-8 必须具有
事实上,我最近发现了 FAS 以外的免疫受体下游的细胞凋亡独立功能。
发现多种免疫受体的激活会引发 caspase-8 介导的 Nedd4- 裂解
结合蛋白 1 (N4BP1),一种新型细胞因子抑制因子,这代表了过程中的关键点。
值得注意的是,N4BP1 的缺失通常不会影响 TRIF 依赖性的 Toll 样子集。
激活 caspase-8 的受体 (TLR)(例如 TLR3 和 TLR4),但细胞因子的产生受损。
用 TLR4 激动剂刺激的 caspase-8 缺陷型巨噬细胞通过 N4BP1 的共同删除而恢复正常。
相反,N4BP1 缺失会导致不依赖 TRIF 的 TLR(例如 TLR1/2、
TLR7 和 TLR9) 不直接激活 caspase-8,因此,caspase-8 裂解 N4BP1 会使 caspase-8 失活。
完整的、未裂解的 N4BP1 的抗炎活性为这一现象提供了新的机制解释。
FADD-caspase-8 突变引起的免疫缺陷,因此无法切割 N4BP1 导致其
细胞因子反应的异常持续和收缩,如 TLR3 和 TLR4 激动剂、肿瘤坏死因子。
(TNF) 还会导致 N4BP1 的 caspase-8 裂解,赋予 TNF 灭活 N4BP1 的能力,
后一发现强调了 TRIF 独立 TLR 产生细胞因子的许可。
TNF 和 TLR 系统之间的分子串扰集中在 N4BP1 的 caspase-8 裂解上。
目前的提案中,我将 N4BP1 抑制细胞因子产生的机制与一系列
在目标 1 中,我将尝试研究在炎症中具有先前已知和未知作用的蛋白质。
破译 N4BP1 控制这种新型激酶依赖性途径活性的机制
在目标 2 中,我将剖析 N4BP1 如何抑制晚期炎症基因。
在目标 3 中,我将探讨其机制和体内后果。
通过 TNF-caspase-8-N4BP1 轴进行信号整合,这些目标将提供新的机制。
解释炎症背后的关键调节回路的见解它们也将有助于启动我的研究。
独立的研究生涯。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alexander Gitlin其他文献
Alexander Gitlin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alexander Gitlin', 18)}}的其他基金
Regulatory control of inflammatory cytokine production by a linear ubiquitin-binding protein
线性泛素结合蛋白对炎症细胞因子产生的调节控制
- 批准号:
10337076 - 财政年份:2021
- 资助金额:
$ 44.25万 - 项目类别:
Regulatory control of inflammatory cytokine production by a linear ubiquitin-binding protein
线性泛素结合蛋白对炎症细胞因子产生的调节控制
- 批准号:
10674329 - 财政年份:2021
- 资助金额:
$ 44.25万 - 项目类别:
Molecular Regulation of Germinal Center B Lymphocytes
生发中心 B 淋巴细胞的分子调控
- 批准号:
8649227 - 财政年份:2014
- 资助金额:
$ 44.25万 - 项目类别:
相似国自然基金
β2AR激动剂与微秒电刺激对大鼠肛提肌线粒体有氧代谢酶及其多模态影像表型的影响研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
环境激素壬基酚对变应性鼻炎的影响及其对GPER特异性激动剂G-1在变应性鼻炎治疗作用中的干扰机制研究
- 批准号:82000963
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
促生长激素释放激素激动剂抑制平滑肌细胞转分化对动脉粥样硬化的影响及机制研究
- 批准号:81900389
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
五羟色胺2C受体激动剂对2型糖尿病小鼠β细胞功能的影响及机制研究
- 批准号:81803644
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
cAMP信号激动剂对恶性胶质瘤血管新生和血管正常化的影响及机制研究
- 批准号:81803568
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
相似海外基金
NHERF1 regulates MRGPRX2/MrgprB2 responses in mast cells
NHERF1 调节肥大细胞中的 MRGPRX2/MrgprB2 反应
- 批准号:
10711042 - 财政年份:2023
- 资助金额:
$ 44.25万 - 项目类别:
PTP1b Inhibition Restores the Innate Anti-tumor Response During Chemotherapy
PTP1b 抑制可恢复化疗期间的先天抗肿瘤反应
- 批准号:
10442910 - 财政年份:2022
- 资助金额:
$ 44.25万 - 项目类别:
The NHERF1-STIM1-Orai1 axis regulates MRGPRX2 responses in mast cells
NHERF1-STIM1-Orai1 轴调节肥大细胞中的 MRGPRX2 反应
- 批准号:
10538916 - 财政年份:2022
- 资助金额:
$ 44.25万 - 项目类别:
Development of ITCH-activating IRAK4 degraders as dual-targeting drug candidates for the treatment of rheumatoid arthritis
开发 ITCH 激活 IRAK4 降解剂作为治疗类风湿性关节炎的双靶点候选药物
- 批准号:
10545911 - 财政年份:2022
- 资助金额:
$ 44.25万 - 项目类别:
PTP1b Inhibition Restores the Innate Anti-tumor Response During Chemotherapy
PTP1b 抑制可恢复化疗期间的先天抗肿瘤反应
- 批准号:
10653166 - 财政年份:2022
- 资助金额:
$ 44.25万 - 项目类别: